Pfizer Announces , $5.4 Billion Deal , to Acquire Global Blood Therapeutics.<br />Pfizer has announced a $5.4 billion deal <br />for the blood disorder drugmaker.<br />NBC reports that the news marks the latest <br />attempt by Pfizer to combat declining demand <br />for COVID-19 products as case numbers fall.<br />The company has seen an unprecedented <br />rise in sales since the global rollout <br />of its COVID-19 vaccine.<br />However, sales have begun to slow <br />since the height of the pandemic.<br />NBC reports that Pfizer is now seeking <br />acquisitions that have the potential to boost <br />sales by billions by the end of the decade.<br />In May, Pfizer acquired migraine drugmaker <br />Biohaven Pharmaceutical Holding for $11.6 billion.<br />The company also recently <br />completed a $6.7 billion deal <br />to purchase Arena Pharmaceuticals.<br />According to NBC, the acquisition <br />of Global Blood Therapeutics would allow <br />Pfizer to boost sales of Oxybryta.<br />In 2019, Oxybryta was first approved <br />as a treatment for Sickle Cell Disease. .<br />An estimated 70,000 to 100,000 people in <br />the United States are affected by Sickle Cell <br />Disease, which is an inherited blood disorder.<br />Following the announcement of the deal,<br />shares of Global Blood rose 4.5%.
